Immunocellular Therapeutics, Ltd. (IMUC) Reports In-Line Q1 Loss of 5c/Share

Immunocellular Therapeutics, Ltd. (NYSE: IMUC) reported Q1 EPS of ($0.05), in-line with the analyst estimate of ($0.05). The net loss for the most recent quarter reflects a charge of $416,000 related to the revaluation of the Company's warrant derivatives.

For earnings history and earnings-related data on Immunocellular Therapeutics, Ltd. (IMUC) click here.

You May Also Be Interested In

• Wells Fargo upgrades S&P 500 Industrials to favorable
• Iovance shares jump in premarket as raised outlook clears consensus views
• Carnival surges on earnings beat and strong 2027 bookings